- Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty’s portfolio - ...
SHANGHAI, Dec. 10, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of ...
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback